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Abstract: 
Silymarin, an extract of the seeds of milk thistle (Silybum marianum), is used as an herbal 
remedy, particularly for hepatoprotection. The main chemical constituents in silymarin are seven 
flavonolignans. Recent studies explored the non-selective methylation of one flavonolignan, 
silybin B, and then tested those analogues for cytotoxicity and inhibition of both cytochrome 
P450 (CYP) 2C9 activity in human liver microsomes and hepatitis C virus infection in a human 
hepatoma (Huh7.5.1) cell line. In general, enhanced bioactivity was observed with the analogues. 
To further probe the biological consequences of methylation of the seven major flavonolignans, a 
series of 7-O-methylflavonolignans were generated. Optimization of the reaction conditions 
permitted selective methylation at the phenol in the 7-position in the presence of each 
metabolite’s 4–5 other phenolic and/or alcoholic positions without the use of protecting groups. 
These 7-O-methylated analogues, in parallel with the corresponding parent compounds, were 
evaluated for cytotoxicity against Huh7.5.1 cells; in all cases the monomethylated analogues 
were more cytotoxic than the parent compounds. Moreover, parent compounds that were 
relatively non-toxic and inactive or weak inhibitors of hepatitis C virus infection had enhanced 
cytotoxicity and anti-HCV activity upon 7-O-methylation. Also, the compounds were tested for 
inhibition of major drug metabolizing enzymes (CYP2C9, CYP3A4/5, UDP-
glucuronsyltransferases) in pooled human liver or intestinal microsomes. Methylation of 
flavonolignans differentially modified inhibitory potency, with compounds demonstrating both 
increased and decreased potency depending upon the compound tested and the enzyme system 
investigated. In total, these data indicated that monomethylation modulates the cytotoxic, 
antiviral, and drug interaction potential of silymarin flavonolignans. 
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1. Introduction 
The historical uses of milk thistle [Silybum marianum (L.) Gaertn. (Asteraceae)], particularly in 
the areas of cancer chemoprevention and hepatoprotection, have been reviewed extensively. 1, 2, 
3, 4, 5, 6, 7 and 8 From a chemistry perspective, silymarin is a crude extract of the seeds and 
affords a mixture of flavonolignans, which are diastereomeric and/or constitutional isomers of 
each other; a separate review explains the nomenclature of the various constituents.9 With 
respect to the purified compounds, there are seven key flavonolignans, which are termed silybin 
A (1), silybin B (3), isosilybin A (5), isosilybin B (7), silychristin (9), isosilychristin (11), and 
silydianin (13; Scheme 1). 
 
Scheme 1. Structures and conditions for the synthesis of 7-O-methylated analogues of the seven 
major flavonolignans from silymarin. 
Recently, members of our team reported enhanced bioactivity of methylated analogues of silybin 
B (3), particularly with respect to assays for cytotoxic and antiviral activities.10 Therein, a non-
selective methylation method using dimethyl sulfate afforded a series of five analogues of silybin 
B: mono-, di-, two different tri-, and tetra-methylated analogues. Since the objective of the 
research at that stage was to explore the biological activity of a few methylated analogues, the 
selectivity of the reaction was not critical. In fact, it was beneficial that those reaction conditions 
were non-selective, as this produced multiple analogues for testing. 
 
The goal of the present study was to expand upon that initial SAR by selectively synthesizing 7-
O-methyl analogues of the seven major flavonolignans (Scheme 1). However, rather than relying 
upon protecting groups, which require two additional synthetic steps for installation and removal, 
it was hypothesized that the inherent reactivity of the molecule could be harnessed to guide the 
selectivity. By judicious choice of reaction conditions, a single position, the C-7-phenol, was 
methylated selectively in the presence of multiple centers with similar reactivity, including 2 or 3 
other phenolic positions, a similarly acidic secondary alcohol, and a primary alcohol. This 
chemoselectivity was comparable for all seven flavonolignans, which enabled a site-specific 
analysis of the importance of the methylated phenol for each compound’s activity in a suite of 
bioassays that probed cytotoxicity, anti-hepatitis C virus (HCV) activity, and inhibition of major 
drug metabolizing enzymes. 
 
2. Results and discussion 
2.1. Chemistry 
The synthesis of 7-O-methyl analogues of the natural flavonolignans was challenging due to the 
possibility of alkylation at more than one hydroxyl group (Scheme 1). Therefore, a variety of 
bases [Cs2CO3, K2CO3, and Diazabicycloundecene (DBU)], electrophilic methylating agents 
(dimethyl carbonate, methyl iodide), solvents (acetone, THF, acetonitrile), temperatures (rt to 75 
°C under standard heating or up to 130 °C using microwave heating), and times (2 h–2 days) 
were examined, all with the goal of minimizing the formation of polymethylated side products. 
Selective monomethylation of the phenolic group at C-7 was possible for all seven major 
flavonolignans over a temperature range of 30–60 °C using methyl iodide in dry acetone in the 
presence of K2CO3. The 7-position was the most reactive for methylation, presumably due to 
both acidity, being an arylogous carboxylic acid, and steric accessibility. While the yields were 
moderate to low, ranging from approximately 20–40%, the reaction conditions were optimized 
for selective monomethylation rather than yield. 
 
2.2. Purification 
Published methods were utilized to isolate the individual flavonolignans as starting materials for 
the methylation reactions.11 To purify the reaction mixtures, a PFP column was used in the 
reverse phase with a range of CH3CN/H2O (0.1% formic acid) gradients until each compound 
was >98% pure by analytical HPLC (Fig. S1; Supplementary data). 
 
2.3. Structure determination 
Structures of the 7-O-methylated analogues were determined using a suite of NMR spectroscopy 
and mass spectrometry experiments (see Table 1 and Table 2 and Supplementary data). Using 
the data for 7-O-methylsilybin A (2) as a representative example, two methoxy singlets were 
apparent at δH 3.78 (3H) and 3.77 (3H), due to the introduced methoxy group at C-7 and the 
natural one at C-3″, respectively. In contrast, the parent flavonolignan silybin A (1) displayed a 
sharp singlet at δH 10.86 for the C-7 phenolic proton signal. Further evidence for the methoxy 
group on C-7 in analogue 2 was observed in the meta-coupled protons at H-6 and H-8 (δH 6.12 
and 6.10, respectively), which were shifted downfield slightly compared to 1 (Table 1). The 13C 
NMR data (Table 2) of each methylated analogue displayed 26 distinct signals, which was one 
more than the non-methylated starting materials, including resonances at δC 56.0 and 55.7 due to 
the two methoxy moieties at C-7 and C-3″, respectively; these assignments were supported by 
HSQC correlations. Moreover, data from the HMBC experiment demonstrated the connectivity 
of the methoxy moieties (Fig. 1), where correlations were observed between the protons at δH 
3.78 to C-7 (δC 167.6) and δH 3.77 to C-3″ (δC 147.6), respectively, verifying that the 
introduced methoxy moiety was at the C-7 position in 2. For each of the analogues, a similar set 
of NMR experiments and data, coupled with comparisons to the data for the natural 
flavonolignans, were utilized to establish that the methoxy moiety was connected at the 7 
position in all of the analogues. Finally, HRMS data supported the introduction of a single 
methyl moiety, where the [M−H]− ion peak for all of the analogues was fourteen mass units 
greater than that of the parent flavonolignans (see experimental).
 
Table 1. 1H NMR data of flavonolignans and 7-O-methylflavonolignans in DMSO-d6 (500 MHz, 30 °C) 
Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
2 5.08, d 
(11.5) 
5.14, d 
(11.5) 
5.08, d 
(11.5) 
5.14, d 
(11.5) 
5.11, d 
(10.9) 
5.16, d 
(10.9) 
5.11, d 
(11.5) 
5.16, d 
(11.5) 
5.02, d 
(11.4) 
5.05, d 
(11.4) 
5.17, d 
(11.9) 
5.22, d 
(11.4) 
4.86, 
dd 
(10.4) 
4.91, 
dd 
(10.4) 
3 4.63, 
dd 
(11.5, 
6.3) 
4.69, 
dd 
(11.5, 
6.3) 
4.61, 
dd 
(11.5, 
6.3) 
4.67, 
dd 
(11.5, 
6.3) 
4.60, 
dd 
(10.9, 
6.3) 
4.66, 
dd 
(10.9, 
6.3) 
4.61, 
dd 
(11.5, 
5.9) 
4.67, 
dd 
(11.5, 
6.3) 
4.52, dd 
(11.4, 
6.4) 
4.58, dd 
(11.4, 
6.3) 
4.64, 
dd 
(11.9, 
6.5) 
4.67, 
dd 
(11.4, 
6.9) 
4.44, 
dd 
(10.4, 
5.4) 
4.48, 
dd 
(10.4, 
5.4) 
6 5.91, d 
(1.7) 
6.12, d 
(1.7) 
5.91, d 
(2.3) 
6.12, d 
(2.3) 
5.92, d 
(2.3) 
6.13, d 
(2.3) 
5.92, d 
(2.0) 
6.13, d 
(2.3) 
5.91, d 
(2.0) 
6.12, d 
(2.3) 
5.93, d 
(1.9) 
6.13, d 
(2.0) 
5.91, d 
(2.5) 
6.12, d 
(1.9) 
8 5.86, d 
(1.7) 
6.10, d 
(1.7) 
5.87, d 
(2.3) 
6.10, d 
(2.3) 
5.89, d 
(2.3) 
6.12, d 
(2.3) 
5.89, d 
(2.0) 
6.12, d 
(2.3) 
5.86, d 
(2.0) 
6.09, d 
(2.3) 
5.88, d 
(1.9) 
6.11, d 
(2.0) 
5.88, d 
(2.5) 
6.11, d 
(1.9) 
2′ 7.09, d 
(1.7) 
7.10, d 
(1.7) 
7.08, d 
(1.8) 
7.10, d 
(2.3) 
7.09, d 
(2.3) 
7.11, d 
(2.3) 
7.10, d 
(1.8) 
7.11, d 
(1.7) 
6.82, d 
(1. 5) 
6.84, d 
(1.2) 
— — 3.44, 
dd 
(4.0, 
2.0) 
3.45, 
dd 
(4.0, 
2.0) 
5′ 6.97, d 
(8.0) 
6.98, d 
(8.6) 
6.97, d 
(8.1) 
6.98, d 
(8.0) 
6.93, d 
(8.6) 
6.94, d 
(8.6) 
6.93, d 
(8.0) 
6.94, d 
(8.0) 
— — 6.75, d 
(8.1) 
6.74, d 
(8.1) 
3.17, 
dd 
(8.9, 
3.0) 
3.19, 
dd 
(6.9, 
3.0) 
6′ 7.00, 
dd (8.0, 
1.7) 
7.01, 
dd (8.6, 
1.7) 
7.02, 
dd (8.1, 
1.8) 
7.02, 
dd (8.0, 
2.3) 
6.98, 
dd (8.6, 
2.3) 
6.99, 
dd (8.6, 
2.3) 
6.98, 
dd (8.0, 
1.8) 
7.00, 
dd (8.0, 
1.7) 
6.87, br 
s 
6.88, br 
s 
6.96, d 
(8.1) 
6.97, d 
(8.1) 
5.92, d 
(8.9) 
6.01, d 
(6.9) 
Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
2′′ 7.01, d 
(1.8) 
7.03, d 
(1.8) 
7.02, d 
(1.7) 
7.04, d 
(1.7) 
7.00, d 
(1.7) 
7.00, d 
(1.7) 
7.00, d 
(2.3) 
7.01, d 
(1.8) 
6.96, d 
(2.0) 
6.96, d 
(1.8) 
6.86, d 
(1.5) 
6.86, d 
(2.0) 
6.75, d 
(2.0) 
6.76, d 
(1.9) 
5′′ 6.80, d 
(8.6) 
6.80, d 
(8.6) 
6.79, d 
(8.6) 
6.80, d 
(8.0) 
6.80, d 
(8.6) 
6.80, d 
(8.0) 
6.80, d 
(8.6) 
6.80, d 
(8.2) 
6.76, d 
(8.4) 
6.76, d 
(8.1) 
6.70, d 
(7.9) 
6.69, d 
(8.5) 
6.63, d 
(8.5) 
6.64, d 
(8.4) 
6′′ 6.86, 
dd (8.6, 
1.8) 
6.86, 
dd (8.6, 
1.8) 
6.86, 
dd (8.6, 
1.7) 
6.86, 
dd (8.0, 
1.7) 
6.86, 
dd (8.6, 
1.7) 
6.85, 
dd (8.0, 
1.7) 
6.86, 
dd (8.6, 
2.3) 
6.85, 
dd (8.2, 
1.8) 
6.80, dd 
(8.4, 
2.0) 
6.81, dd 
(8.1, 
1.8) 
6.76, 
dd 
(7.9, 
1.5) 
6.76, 
dd 
(8.5, 
2.0) 
6.55, 
dd 
(8.5, 
2.0) 
6.56, 
dd 
(8.4, 
1.9) 
7′′ 4.90, d 
(7.5) 
4.91, d 
(7.5) 
4.90, d 
(7.5) 
4.91, d 
(7.5) 
4.91, d 
(8.1) 
4.91, d 
(7.5) 
4.91, d 
(7.5) 
4.92, d 
(7.5) 
5.46, d 
(7.0) 
5.46, d 
(6.9) 
5.58, d 
(2.5) 
5.57, d 
(2.5) 
3.31, 
br s 
3.31, 
br s 
8′′ 4.17, 
ddd 
(7.5, 
4.6, 
2.3) 
4.18, 
ddd 
(7.5, 
4.6, 
2.3) 
4.16, 
ddd 
(7.5, 
4.1, 
2.3) 
4.17, 
ddd 
(7.5, 
4.6, 
2.3) 
4.16, 
ddd 
(8.1, 
4.6, 
2.3) 
4.17, 
ddd 
(7.5, 
4.0, 
2.3) 
4.17, 
ddd 
(7.5, 
4.6, 
2.3) 
4.17, 
ddd 
(7.5, 
4.6, 
1.7) 
3.47, 
ddd 
(12.6, 
12.0, 
7.0) 
3.47, 
ddd 
(12.6, 
12.0, 
6.9) 
3.67, m 3.67, 
m 
2.72, 
br s 
2.73, 
br s 
9′′a 3.53, 
ddd 
(10.3, 
5.2, 
2.3) 
3.53, 
ddd 
(10.3, 
5.2, 
2.3) 
3.53, 
ddd 
(9.8, 
4.6, 
2.3) 
3.54, 
ddd 
(12.0, 
5.2, 
2.3) 
3.53, 
ddd 
(12.0, 
4.6, 
2.3) 
3.53, 
ddd 
(12.0, 
4.6, 
2.3) 
3.54, 
ddd 
(11.9, 
5.2, 
2.3) 
3.53, 
ddd 
(12.0, 
5.2, 
1.7) 
3.72, 
ddd 
(12.6, 
10.9, 
5.0) 
3.72, 
ddd 
(12.6, 
10.9, 
5.2) 
3.68, m 3.68, 
m 
4.12, 
dd 
(8.0, 
3.0) 
4.13, 
dd 
(8.0, 
3.0) 
9′′b 3.33, m 3.34, m 3.33, m 3.33, m 3.33, m 3.33, m 3.33, m 3.33, m 3.63, 
ddd 
(12.6, 
10.9, 
5.6) 
3.63, 
ddd 
(12.6, 
10.9, 
5.7) 
3.45, m 3.44, 
m 
3.78, d 
(8.0) 
3.78, d 
(8.0) 
Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
7-OCH3 — 3.78, s — 3.78, s — 3.79, s — 3.79, s — 3.78, s — 3.80, s — 3.79, s 
3′′-
OCH3 
3.77, s 3.77, s 3.77, s 3.77, s 3.78, s 3.77, s 3.77, s 3.77, s 3.76, s 3.76, s 3.70, s 3.69, s 3.73, s 3.74, s 
3-OH 5.83, d 
(6.3) 
5.90, d 
(6.3) 
5.83, d 
(6.3) 
5.89, d 
(6.3) 
5.83, d 
(6.3) 
5.91, d 
(6.3) 
5.84, d 
(5.9) 
5.91, d 
(6.3) 
5.77, d 
(6.4) 
5.81, d 
(6.3) 
5.76, d 
(6.5) 
5.81, d 
(6.9) 
6.02, d 
(6.3) 
6.04, d 
(6.3) 
5-OH 11.90, s 11.86, s 11.90, s 11.87, s 11.90, s 11.87, s 11.90, s 11.87, s 11.91, s 11.87, s 11.93, 
s 
11.90, 
s 
11.81, 
s 
11.77, 
s 
7-OH 10.86, s — 10.86, s — 10.85, s — 10.86 s — 10.84, s — 10.98, 
s 
— 10.91, 
s 
— 
4′′-
OH 
9.18, s 9.19, s 9.17, s 9.18, s 9.15, s 9.18, s 9.16, s 9.18, s 9.03, s 9.02, s 9.00, s 8.99, s 8.79, s 8.79, s 
9′′-
OH 
4.97, 
dd (5.7, 
5.2) 
4.98, 
dd (5.7, 
5.2) 
4.98, 
dd (5.7, 
4.6) 
4.98, 
dd (5.7, 
5.2) 
4.95, 
dd (5.7, 
4.6) 
4.97, 
dd (5.7, 
4.6) 
4.96, 
dd (5.5, 
5.0) 
4.97, 
dd (4.6, 
5.2) 
5.01, dd 
(5.6, 
5.0) 
5.01, dd 
(5.7, 
5.2) 
5.07, 
br dd 
(4.5, 
2.0) 
5.06, 
dd 
(6.5, 
4.5) 
  
3′-OH — — — — — — — — — — — — 7.19, s 7.17, s 
Chemical shifts in δ, coupling constants in Hz 
 
 
 
 
Table 2. 13C NMR data of flavonolignans and 7-O-methylated analogues in DMSO-d6 (125 MHz, 30 °C) 
Position Type 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
2 CH 82.6 82.7 82.5 82.7 82.5 82.7 82. 5 82.7 83.3 83.4 79.9 80.0 81.7 81.8 
3 CH 71.4 71.5 71.4 71.5 71.5 71.6 71.5 71.6 71.7 71.8 71.5 71.7 70.8 71.0 
4 C 197.8 198.5 197.7 198.5 197.8 198.4 197.8 198.4 197.8 198.4 198.2 198.7 196.5 197.6 
4a C 100.4 101.4 100.4 101.4 100.5 101.4 100.5 101.4 100.5 101.4 100.6 101.5 100.3 101.2 
5 C 163.3 163.0 163.3 163.0 163.3 163.0 163.3 163.0 163.3 163.0 163.4 163.1 163.4 163.0 
6 CH 96.1 95.0 96.1 94.9 96.1 95.0 96.1 95.0 96.0 94.9 96.1 95.0 96.2 95.2 
7 C 167.1 167.6 166.9 167.6 166.9 167.6 166.9 167.6 166.8 167.5 166.8 167.6 166.9 167.6 
8 CH 95.1 93.9 95.0 93.9 95.1 93.9 95.1 93.9 95.0 93.8 95.1 93.9 95.0 93.8 
8a C 162.5 162.4 162.4 162.4 162.5 162.4 162.5 162.4 162.6 162.5 162.6 162.5 162.0 162.0 
1′ C 130.1 129.9 130.1 130.0 130.3 130.2 130.3 130.2 130.0 129.8 124.5 124.4 139.5 139.4 
2′ CH 116.6 116.7 116.6 116.7 116.5 116.6 116.5 116.5 115.6 115.7 128.9 128.9 48.6 48.7 
3′ C 143.3 143.3 143.2 143.2 142.9 142.9 142.9 142.9 146.4 146.4 141.6 141.6 96.7 96.7 
4′ C 143.7 143.7 143.6 143.7 143.9 143.9 143.9 143.9 140.7 140.7 145.9 145.8 201.9 201.9 
Position Type 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
5′ CH 116.3 116.4 116.3 116.4 116.4 116.5 116.5 116.4 129.1 129.1 116.1 116.1 53.4 53.3 
6′ CH 121.4 121.5 121.1 121.2 120.9 121.0 120.9 121.0 115.4 115.4 119.5 119.4 124.0 124.0 
1′′ C 127.5 127.5 127.5 127.5 127.5 127.5 127.5 127.5 132.4 132.4 132.8 132.8 133.0 133.0 
2′′ CH 111.6 111.6 111.6 111.6 111.7 111.7 111.7 111.7 110.4 110.9 110.2 110.3 112.4 112.4 
3′′ C 147.6 147.6 147.6 147.6 147.6 147.6 147.6 147.6 147.5 148.1 147.5 147.5 147.1 147.2 
4′′ C 147.0 147.0 147.0 147.0 147.0 147.0 147.0 147.0 147.1 147.7 146.3 146.3 145.1 145.1 
5′′ CH 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.1 115.1 114.9 115.0 
6′′ CH 120.5 120.6 120.5 120.5 120.5 120.5 120.5 120.4 118.7 118.7 118.5 118.6 120.3 120.3 
7′′ CH 75.9 75.9 75.8 75.9 75.9 75.9 75.9 75.9 87.0 87.5 86.4 86.4 46.0 46.0 
8′′ CH 78.1 78.1 78.1 78.1 78.0 78.0 78.0 78.0 53.4 53.9 52.0 51.9 44.0 44.0 
9′′ CH2 60.2 60.2 60.2 60.2 60.2 60.2 60.2 60.2 63.0 63.5 63.5 63.5 72.8 72.8 
3′′-OCH3 CH3 55.7 55.7 55.7 55.7 55.7 55.7 55.7 55.7 55.6 55.6 55.6 55.6 55.4 55.4 
7-OCH3 CH3 — 56.0 — 56.0 — 56.0 — 56.0 — 55.9 — 56.0 — 56.0 
Chemical shifts in δ. In compounds 9 and 10, position 5′ is quaternary; in compounds 11 and 12, position 2′ is quaternary.
 
Figure 1. Key HMBC correlations of 7-O-methylsilybin A (2). 
2.4. Biological studies 
2.4.1. Cytotoxicity and cell viability 
In comparing the cytotoxicity profiles of 7-O-methylated analogues versus parental counterparts 
(Table 3), addition of a single methyl group increased cytotoxicity against human hepatoma cells 
(Huh7.5.1). These findings were consistent with an earlier pilot study that examined a series of 
mono-, di-, tri- and tetra-methylated analogues of silybin B (3).10 Silychristin (9), isosilychristin 
(11), and silydianin (13) have been reported to be relatively non-toxic compared to the other 
silymarin flavonolignans.12 In the current study, marked increases in the cytotoxicity of 
silydianin (13), silybin A (1), and isosilybin A (5) were observed upon methylation (compounds 
14, 2, and 6, with 13.8-, 8.4-, and 6.1-fold, respectively). However, the 7-O-methylation of 
isosilybin B (7) did not produce a pronounced increase in cytotoxicity (i.e., compound 8), which 
was interesting given that 7 has been shown to be the most cytotoxic of the parent 
flavonolignans, particularly in assays for prostate cancer chemoprevention. 12, 13, 14, 15, 16 and 
17 
Table 3. Cytotoxic activity of flavonolignans and 7-O-methylated analogues against human 
hepatoma (Huh7.5.1) cells 
Compound IC50 values (μM) Fold changea,b 
Silybin A (1) 80.0  
7-O-Methylsilybin A (2) 9.5 8.4 
Silybin B (3) 68.7  
7-O-Methylsilybin B (4) 12.7 5.5 
Isosilybin A (5) 80.0  
7-O-Methylisosilybin A (6) 13.2 6.1 
Isosilybin B (7) 27.0  
Compound IC50 values (μM) Fold changea,b 
7-O-Methylisosilybin B (8) 18.0 1.5 
Silychristin (9) >130  
7-O-Methylsilychristin (10) 66.4 >2 
Isosilychristin (11) >130  
7-O-Methylisosilychristin (12) 27.6 >4.7 
Silydianin (13) >130  
7-O-Methylsilydianin (14) 9.4 13.8 
Resveratrolc 10.6  
a The fold change was calculated by dividing the IC50 value for the parent flavonolignan by the 
IC50 value for the corresponding 7-O-methylated analogue. 
b The average fold change for all analogues was approximately 6. 
c Typical average value as a positive control for the assay. 
2.4.2. Antiviral activity 
In evaluating the anti-HCV profiles of these compounds (Fig. 2), some of the methylated 
flavonolignans displayed improved anti-HCV activity [i.e. 7-O-methylsilychristin (10), 7-O-
methylisosilychristin (12)] relative to the corresponding parent compounds. In particular, 
silychristin (9), isosilychristin (11), and silydianin (13) did not show appreciable antiviral 
activity until they were methylated (i.e., 10, 12, and 14). On the other hand, for parent 
compounds that were active in blocking HCV activity, such as silybin A (1), silybin B (3), and 
isosilybin A (5), the activities of their methylated counterparts were either retained (2) or 
reduced (4 and 6). The most toxic parent compound, isosilybin B (7), had a slight enhancement 
of both antiviral activity and cytotoxicity (Table 3) by methylation (compound 8). Thus, it 
appeared that HCV antiviral activity tracked with cytotoxicity. That is, as compounds became 
more toxic, the more likely antiviral activity was detected. However, that is not to say that 
antiviral activity coincided with cytotoxicity, as we were always able to detect anti-HCV activity 
that was independent of cytotoxicity. We hypothesize that flavonolignans target shared cellular 
functions that confer both cytotoxic and antiviral activities, although this requires further 
experimentation to verify. 
 
Figure 2. Antiviral profile of parent and 7-O-methyl flavonolignans. Huh7.5.1 cells were infected 
with JFH-1 at a multiplicity of infection of 0.05. Virus inoculum was removed after 5 h and 
compounds were added. Cultures were incubated for 72 h before protein lysates were analyzed 
for HCV core protein expression by Western blot analysis. Detection of actin protein served as a 
protein loading control. Panel A depicts an example of a parent compound that lacked anti-HCV 
activity (9) and acquired anti-HCV activity upon methylation (10). Panel B depicts an example 
of a parent compound that had anti-HCV activity (3) and decreased anti-HCV activity upon 
methylation (4). The graphs below panels A and B present quantitation of HCV core pixel 
intensity following normalization to actin pixel intensity, expressed as percent inhibition relative 
to DMSO controls. Graphs below panel A depict parent compounds that lacked anti-HCV 
activity (9, 11, 13) and acquired anti-HCV activity upon methylation (10, 12, 14). Graphs below 
panel B depict parent compounds that had anti-HCV activity (1, 3, 5, 7), and retained (2), 
decreased (4, 6), or enhanced (8) anti-HCV activity upon methylation. Doses used were derived 
from toxicity data, such that two non-toxic concentrations and one near the IC50 value were 
evaluated in the antiviral assay. Concentrations for compounds 1, 3, and 5: 6.2, 20.7, 62.1 μM. 
Concentrations for compounds 2, 4, 6, and 14: 0.8, 2.7, 8.0 μM. Concentrations for compounds 7 
and 8: 1.6, 5.4, 16.1 μM. Concentrations for compounds 9, 11, 12 and 13 12.4, 41.4, 124.2 μM. 
Concentrations for compound 10: 6.0, 20.1, 60.3 μM. 
2.4.3. Inhibition of drug metabolizing enzymes 
The propensity of methylation at the 7-O position to alter drug interaction liability was evaluated 
by testing all compounds as inhibitors of major drug metabolizing enzymes using the probe 
substrates (S)-warfarin (CYP2C9; Fig. 3), midazolam (CYP3A4/5; Fig. 4), and 4-
methylumbelliferone (UGT; Fig. 5) and human liver or intestinal microsomes (HLM or HIM, 
respectively). Although CYP2C9 and CYP3A4/5 are expressed in both the human intestine and 
liver,18 intestinal CYP2C9 has not yet been shown to have clinical impact on drug disposition in 
vivo. As such, HLM were selected for incubations with (S)-warfarin, whereas HIM were selected 
for incubations with midazolam. 
 
Figure 3. Effects of selected flavonolignans and 7-O-methylated analogues on CYP2C9-
mediated (S)-warfarin 7-hydroxylation in human liver microsomes (HLM). Incubation mixtures 
consisted of HLM (0.1 mg/mL), (S)-warfarin (4 μM), flavonolignan or 7-O-methylated analogue 
(10 or 100 μM; hatched and solid bars, respectively), and potassium phosphate buffer (0.1 M, pH 
7.4). Reactions were initiated by the addition of NADPH (1 mM) and were terminated after 30 
min with ice-cold MeOH containing 4-chlorowarfarin as internal standard. Activity in the 
presence of vehicle control (0.75% methanol, v/v) was 2.5 ± 0.1 pmol/min/mg microsomal 
protein. Bars and error bars denote means and SDs, respectively, of triplicate incubations. ∗p < 
0.05, 10 versus 100 μM; #p < 0.05, flavonolignan versus 7-O-methylated analogue at 100 μM 
(two-way ANOVA with Bonferroni adjustment). 
 
 
Figure 4. Effects of selected flavonolignans and 7-O-methylated analogues on CYP3A-mediated 
midazolam 1′-hydroxylation in human intestinal microsomes (HIM). Incubation mixtures 
consisted of HIM (0.05 mg/ml), midazolam (4 μM), flavonolignan or 7-O-methylated analogue 
(10 or 100 μM; hatched and solid bars, respectively), and potassium phosphate buffer (0.1 M, pH 
7.4) supplemented with magnesium chloride (3.3 mM). Reactions were initiated by the addition 
of NADPH (1 mM) and were terminated after 4 min with ice-cold acetonitrile containing 
alprazolam as internal standard. Activity in the presence of vehicle control (0.1% DMSO, v/v) 
was 700 ± 100 pmol/min/mg microsomal protein. Bars and error bars denote means and SDs, 
respectively, of triplicate incubations. ∗p <0.05, 10 versus 100 μM; #p < 0.05, flavonolignan 
versus 7-O-methylated analogue at 100 μM (two-way ANOVA with Bonferroni adjustment). 
 
Figure 5. Effects of selected flavonolignans and 7-O-methylated analogues on UGT-mediated 4-
methylumbelliferone (4-MU) glucuronidation in human liver microsomes (HLM). Incubation 
mixtures consisted of HLM (0.4 mg/mL), 4-MU (100 μM), flavonolignan or 7-O-methylated 
analogue (10 or 100 μM; hatched and solid bars, respectively), bovine serum albumin (BSA, 
0.05%), and Tris–HCl buffer (0.1 M, pH 7.5) supplemented with magnesium chloride (5 mM). 
Reactions were initiated by the addition of UDPGA (4 mM) followed by fluorescence analysis of 
4-MU depletion over a period of 10 min. Activity in the presence of vehicle control (0.2% 
MeOH, v/v) was 8.0 ± 0.4 nmol/min/mg microsomal protein. Bars and error bars denote means 
and SDs, respectively, of triplicate incubations. ∗p < 0.05, 10 versus 100 μM; #p < 0.05, 
flavonolignan versus 7-O-methylated analogue at 100 μM (two-way ANOVA with Bonferroni 
adjustment). 
All flavonolignans and 7-O-methylated analogues showed concentration-dependent inhibition of 
CYP activity ( Figure 3 and Figure 4), except for isosilybin A (5) against CYP2C9 activity (Fig. 
3). The parent versus methylated analogue pairs at 100 μM differed in inhibition potency except 
for silybin B (3) versus 7-O-methylsilybin B (4) against CYP2C9 activity (Fig. 3), silydianin 
(13) versus 7-O-methylsilydianin (14) against CYP3A4/5 activity, and silychristin (9) versus 7-
O-methylsilychristin (10) against CYP3A4/5 activity (Fig. 4). Amongst the analogue series, 
compounds with an ‘iso’ configuration inhibited the CYP enzymes ( Figure 3 and Figure 4) to a 
greater extent than corresponding regioisomers. For example, 7-O-methylisosilybin A (6), 7-O-
methylisosilybin B (8), and 7-O-methylisosilychristin (12) were more potent against CYP 
activities than 7-O-methylsilybin A (2), 7-O-methylsilybin B (4), and 7-O-methylsilychristin 
(10). Sulfaphenazole and ketoconazole, known potent inhibitors of CYP2C9 and CYP3A4/5 
activity, respectively, inhibited corresponding activities by 67% and 81% (data not shown). 
 
Compared to the CYPs, inhibition of UGTs was less extensive (Fig. 5). However, in general, the 
parent compounds were more potent than the analogues. For example, silybin A (1), silybin B 
(3), and silydianin (13) at 100 μM were more potent than the respective methylated analogues 
(i.e., 2, 4, and 14), suggesting that methylation reduced activity against UGT. One exception was 
7-O-methylisosilychristin (12), which was more potent than isosilychristin (11). Diclofenac, a 
non-specific inhibitor of the UGTs, inhibited activity by 56% (data not shown). 
 
Collectively, CYP2C9 activity was most sensitive to inhibition, by both parent flavonolignans 
and corresponding methylated analogues, followed by CYP3A4/5 and UGT activity (up to 91%, 
72%, and 44% inhibition, respectively). 7-O-Methylation of these isolated flavonolignans 
highlights the importance of this metabolically labile site, providing mechanistic insight into the 
enzyme–ligand interaction. 
 
3. Conclusion 
In summary, a series of 7-O-methyl flavonolignan derivatives has been synthesized selectively, 
and this study is the first to examine methylation of all seven of the major flavonolignans in 
silymarin. All the derivatives showed cytotoxic effects against human hepatoma cells. The most 
potent analogue was 7-O-methylsilybin A, which exhibited an IC50 value of 9.5 μM compared 
with parent silybin A with an IC50 value of 80 μM. In terms of anti-HCV activity, parent 
compounds with minimal to no antiviral activity (i.e., 9, 11, 13) showed increased antiviral 
activity when converted to the 7-O-methyl derivatives. For these compounds, acquisition of 
antiviral activity by 7-O-methylation was associated with enhanced cytotoxicity. In contrast, 
parent compounds with anti-HCV activity either retained (1), decreased (3, 5), or slightly 
increased (7) activity upon methylation. 7-O-Methylation differentially modified the inhibitory 
potency of flavonolignans towards major drug metabolizing enzymes, with compounds 
demonstrating increased, decreased, or no change in potency depending upon the enzyme system 
investigated. Despite inconsistent patterns, the differences observed between parent and analogue 
suggested the importance of the 7-position. Cumulatively, these data suggested that silymarin-
derived compounds exert pleiotropic effects on cells. Ongoing efforts are focusing on how these 
compounds affect cellular metabolic processes that culminate in cytotoxicity, antiviral activity, 
and drug metabolism inhibition. 
 
4. Experimental 
4.1. General experimental procedures 
Optical rotation and UV data were acquired on a Rudolph Research Autopol® III polarimeter 
and a Varian Cary 3 UV–vis spectrophotometer, respectively. All NMR experiments were 
conducted in DMSO-d6 at 30 °C using a JEOL ECA-500 (operating at 500 MHz for 1H and 125 
MHz for 13C). HRESIMS data were measured using an electrospray ionization (ESI) source 
coupled to a Q-TOF Premier mass spectrometer (Waters Corp., Milford, MA, USA) in negative 
ionization mode via a liquid chromatographic/autosampler system that consisted of an Acquity 
UPLC system (Waters Corp.). HPLC was carried out on Varian Prostar HPLC systems equipped 
with Prostar 210 pumps and a Prostar 335 photodiode array detector (PDA), with data collected 
and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2). For 
preparative HPLC, a YMC ODS-A (5 μm, 250 × 20 mm; Waters Corp.) column was used at a 7 
mL/min flow rate and a Phenomenex PFP (pentafluorophenyl propyl; 5 μm; 250 × 21 mm) 
column was used at a 21.2 mL/min flow rate. For analytical HPLC, a YMC ODS-A (5 μm; 150 × 
4.6 mm) column and a PFP (5 μm; 150 × 4.6 mm) column were used, both at a 1 mL/min flow 
rate. All reactions were carried out in a N2 atmosphere under anhydrous conditions. 
 
4.2. Chemistry, synthesis and purification 
The individual flavonolignans were isolated from milk thistle extract (silymarin) in >98% purity 
as described in detail previously.11 To purify the reaction mixtures, two different reverse-phase 
columns [ODS-A C18 (5 μm; 250 × 20 mm) and PFP (5 μm; 250 × 21 mm)] were examined; the 
latter gave the best results according to peak symmetry and resolution when using acetonitrile as 
the organic modifier (data not shown). Accordingly, each 7-O-methylated flavonolignan 
analogue was purified until >98% pure, as measured by analytical HPLC (Fig. S1; 
Supplementary data). 7-O-methylsilybin A (2) and 7-O-methylisosilybin A (6) were purified 
using a gradient of 30:70 to 50:50 CH3CN/H2O (0.1% formic acid) over 30 min. 7-O-
methylsilybin B (4) was purified using a gradient of 20:80 to 40:60 CH3CN/H2O (0.1% formic 
acid) over 30 min. 7-O-methylisosilybin B (8) was purified using 20:80 to 60:40 CH3CN/H2O 
(0.1% formic acid) over 40 min. 7-O-Methylsilychristin (10) and 7-O-methylsilydianin (12) were 
purified using a gradient of 20:80 to 42:58 CH3CN/H2O (0.1% formic acid) over 45 min. 7-O-
Methylisosilychristin (14) was purified using a gradient of 15:85 to 36:64 CH3CN/H2O (0.1% 
formic acid) over 50 min. 
 
4.2.1. 7-O-Methylsilybin A (2) 
To a 150 mL three-neck round-bottom flask, silybin A (122 mg, 0.253 mmol) and K2CO3 (293 
mg, 2.03 mmol) were dissolved in acetone (80 mL, 0.003 M). After stirring for 10 min, CH3I 
(244 μL, 3.95 mmol) was added dropwise. The reaction mixture was heated at reflux under N2 
for 3 h and monitored by HPLC. After cooling to rt, the reaction was quenched by the addition of 
2% aqueous HCl (pH 1.5) and diluted with H2O (125 mL). The mixture was extracted with 
EtOAc (2 × 80 mL). The organic phases were combined and dried over Na2SO4, filtered, and 
then the solvent was removed under reduced pressure. The compounds were purified as 
described in Section 2.2. Yield: 51 mg, 41%; white solid; View the MathML source +20 (c 0.1, 
MeOH); UV (MeOH) λmax (log ε) 218 (4.2), 287 (4.1) nm; CD (MeOH) λext (Δε) 237 (−3.3), 
296 (−9.2), 330 (1.7) nm; 1H and 13C NMR data, see Table 1 and Table 2 and Figs. S2 and S3; 
HMBC data, see Figs. 1 and S4; HRESIMS m/z 495.1281 [M−H]− (calcd for C26H23O10 
495.1297). 
 
4.2.2. 7-O-Methylsilybin B (4) 
In a manner that was otherwise consistent with the preparation and purification of 2, compound 3 
was reacted with 15 equiv of CH3I at reflux for 3.5 h to yield compound 4. Yield: 10 mg, 33%; 
white solid; View the MathML source +7.7 (c 0.2, MeOH); UV (MeOH) λmax (log ε) 230 (4.0) , 
287 (4.0) nm; CD (MeOH) λext (Δε) 230 (8.6), 296 (−9.2), 334 (1.3) nm; 1H and 13C NMR 
data, see Table 1 and Table 2 and Figs. S5 and S6; HMBC data, see Figs. S7 and S23; HRESIMS 
m/z 495.1290 [M−H]− (calcd for C26H23O10 495.1297). 
 
4.2.3. 7-O-Methylisosilybin A (6) 
In a manner that was otherwise consistent with the preparation and purification of 2, compound 5 
was reacted with 2 equiv of CH3I at 30 °C for 2.5 h to yield compound 6. Yield: 22 mg, 21%; 
white solid; View the MathML source + 46 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 214 (4.1), 
287 (4.0) nm; CD (MeOH) λext (Δε) 236 (−0.9), 296 (−5.7), 331 (0.7) nm; 1H and 13C NMR 
data, see Table 1 and Table 2 and Figs. S8 and S9; HMBC data, see Figs. S10 and S23; 
HRESIMS m/z 495.1292 [M−H]− (calcd for C26H23O10 495.1297). 
 
4.2.4. 7-O-Methylisosilybin B (8) 
In a manner that was otherwise consistent with the preparation and purification of 2, compound 7 
was reacted with 4 equiv of CH3I at 40 °C for 2.5 h to yield compound 8. Yield: 12 mg, 24%; 
white solid; View the MathML source −17.4 (c 0.09, MeOH); UV (MeOH) λmax (log ε) 211 
(4.1), 287 (3.8) nm; CD (MeOH) λext (Δε) 229 (1.8), 294 (−4.2), 331 (−0.1) nm; 1H and 13C 
NMR data, see Table 1 and Table 2 and Figs. S11 and S12; HMBC data, see Figs. S13 and S23; 
HRESIMS m/z 495.1294 [M−H]− (calcd for C26H23O10 495.1297). 
 
4.2.5. 7-O-Methylsilychristin (10) 
In a manner that was otherwise consistent with the preparation and purification of 2, compound 9 
was reacted with 12 equiv of CH3I at reflux for 2 h to yield compound 10. Yield: 41 mg, 40%; 
white solid; View the MathML source +56.6 (c 0.06, MeOH); UV (MeOH) λmax (log ε) 215 
(4.0), 288 (3.8) nm; 1H and 13C NMR data, see Table 1 and Table 2 and Figs. S14 and S15; 
HMBC data, see Figs. S16 and S23; HRESIMS m/z 495.1284 [M−H]− (calcd for C26H23O10 
495.1297). 
 
4.2.6. 7-O-Methylisosilychristin (12) 
In a manner that was otherwise consistent with the preparation and purification of 2, compound 
11 was reacted with 24 equiv of CH3I at 40 °C for 2 h to yield compound 12. Yield: 15 mg, 
29%; white solid; View the MathML source +144.4 (c 0.05, MeOH); UV (MeOH) λmax (log ε) 
212 (4.1), 288 (3.7) nm; 1H and 13C NMR data, see Table 1 and Table 2 and Figs. S17 and S18; 
HMBC data, see Figs. S19 and S23; HRESIMS m/z 495.1284 [M−H]− (calcd for C26H23O10 
495.1297). 
 
4.2.7. 7-O-Methylsilydianin (14) 
In a manner that was otherwise consistent with the preparation and purification of 2, compound 
13 was reacted with 12 equiv of CH3I at reflux for 2 h to yield compound 14. Yield: 20 mg, 
33%; white solid; View the MathML source +157.9 (c 0.06, MeOH); UV (MeOH) λmax (log ε) 
207 (3.9), 288 (3.6) nm; 1H and 13C NMR data, see Table 1 and Table 2 and Figs. S20 and S21; 
HMBC data, see Figs. S22 and S23; HRESIMS m/z 495.1284 [M−H]− (calcd for C26H23O10 
495.1297). 
 
4.3. Biological assays 
4.3.1. Antiproliferative assay 
The antiproliferative/cytotoxic activities of all compounds were examined against a human 
hepatoma cell line, Huh7.5.1,19 as described previously.10 Briefly, 10,000 cells per well were 
plated in 96-well plates, and following overnight incubation, were incubated with increasing 
concentrations of compounds. Cell viability was measured 72 h later using the ATPlite kit, as 
described previously.12 Each IC50 value was evaluated via the measurement of three replicates 
over nine different concentrations, ranging from 0 to 62.5 μM, with the IC50 values calculated 
by linear regression using GraphPad Prism. 
 
4.3.2. Antiviral assay 
Cells (150,000) were plated in 12-well plates, and the next day cells were infected with JFH-1, a 
HCV that grows well in Huh7.5.1 cells, at a multiplicity of infection of 0.05 focus forming units 
per cell. Virus inocula were removed 5 h post-infection and replaced with fresh medium 
containing test compounds. Protein lysates were harvested 72 h later, and HCV proteins were 
detected by Western blot analyses as described previously.12 Importantly, total protein content 
of each sample was determined, and equal amounts of total protein lysates were run on protein 
gels prior to Western blotting. 
 
4.3.3. Inhibition of drug metabolizing enzymes 
Milk thistle flavonolignans and 7-O-methylated analogues were evaluated as inhibitors of 
CYP2C9, CYP3A4/5, and UDP-glucuronosyltransferase (UGT) activity using the probe 
substrates (S)-warfarin, midazolam, and 4-methylumbelliferone (4-MU), respectively. Inhibition 
of CYP2C9 activity. Incubation mixtures consisted of pooled HLM (0.1 mg/mL microsomal 
protein), (S)-warfarin (4 μM), flavonolignan or 7-O-methylated analogue (10 or 100 μM), and 
potassium phosphate buffer (100 mM, pH 7.4). The CYP2C9 inhibitor sulfaphenazole (1 μM) 
was used as a positive control. Control incubation mixtures contained 0.75% MeOH (v/v) in 
place of flavonolignan/7-O-methylated flavonolignan or sulfaphenazole. Incubation mixtures 
were analyzed for 7-hydroxywarfarin by LC/MS–MS as described previously. 20 and 
21Inhibition of CYP3A4/5 activity. Incubation mixtures consisted of pooled HIM (0.05 mg/mL 
microsomal protein), midazolam (4 μM), flavonolignans or 7-O-methylated analogue (10 or 100 
μM), and potassium phosphate buffer (100 mM, pH 7.4) supplemented with magnesium chloride 
(3.3 mM). The CYP3A4/5 inhibitor ketoconazole (1 μM) was used as a positive control. Control 
incubation mixtures contained 0.1% DMSO (v/v) in place of flavonolignan/7-O-methylated 
flavonolignan or ketoconazole. Incubation mixtures were analyzed for 1′-hydroxymidazolam by 
LC/MS–MS as described previously. 22 and 23Inhibition of UGT activity. Incubation mixtures 
consisted of pooled HLM (0.4 mg/mL microsomal protein), 4-MU (100 μM), flavonolignan or 7-
O-methylated analogue (10 or 100 μM), bovine serum albumin (BSA, 0.05%), and Tris–HCl 
buffer (0.1 M, pH 7.5) supplemented with magnesium chloride (5 mM). The UGT inhibitor 
diclofenac (400 μM) was used as a positive control. Control incubation mixtures contained 0.2% 
MeOH (v/v) in place of flavonolignan/7-O-methylated flavonolignan or diclofenac. Incubation 
mixtures were analyzed for 4-MU depletion by fluorescence as described previously.24 
 
Data were analyzed statistically using SigmaStat (version 3.5; Systat Software, Inc., San Jose, 
CA) and are presented as means ± SDs of triplicate incubations. Concentration-dependent 
inhibition of each flavonolignan/7-O-methylated analogue and comparisons between 
flavonolignan and 7-O-methylated analogue at 100 μM were evaluated by two-way analysis of 
variance (ANOVA) with Bonferroni adjustment for multiple comparisons; p <0.05 was 
considered significant. 
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